类药物发现的最新进展:新策略和有针对性的蛋白质降解
Katarina Vrbnjak1, Raj Nayan Sewduth1
1VIB-KU Leuven Center for Cancer Biology (VIB), 3000 Leuven, Belgium.
Pharmaceutics
|November 27, 2024
概括
新的计算和湿实验室方法,包括生物信息学和多组学,加速类药物发现. 这些方法提高了效率,针对具有挑战性的蛋白质相互作用,并为新疗法提供了针对性蛋白质降解.
科学领域:
- 药理学和药物发现
- 生物技术是生物技术.
- 计算生物学 计算生物学
背景情况:
- 传统的类药物发现方法往往是低效和昂贵的.
- 针对蛋白质与蛋白质相互作用仍然是药物开发中的一个重大挑战.
- 新兴技术为更精确,更有效的治疗策略提供了新的途径.
研究的目的:
- 审查用于类药物发现的新湿实验室和计算多原子方法.
- 提供使用这些先进技术识别的治疗剂的概述.
- 讨论基于的治疗方法的潜在应用和交付.
主要方法:
- 计算机辅助的药物发现和高通量查.
- 基因编辑技术和多omics方法.
- 生物信息学用于分析复杂的生物数据.
- 针对蛋白质分解的向嵌合体 (PROTACs) 的开发,用于向蛋白质降解.
主要成果:
- 显著提高了发现的效率,成本效益和可靠性.
- 提高了针对具有挑战性的蛋白质-蛋白质相互作用的能力.
- 通过向蛋白质降解开发具有前所未有的特异性的新型治疗剂.
结论:
- 先进的计算和多原子策略正在彻底改变类药物发现.
- 基于的疗法,包括PROTACs,为向以前无法药物治疗的蛋白质提供了多功能解决方案.
- 对治疗输送方法的进一步研究将提高类药物的临床实用性.
更多相关视频
08:48Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation
Published on: January 26, 2016
11.8K
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11.3K
相关概念视频
Regulated Protein Degradation
2.5K
2.5K
Drug Discovery: Overview
7.5K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.5K
The Proteasome
8.5K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
8.5K
Targets for Drug Action: Overview
6.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.0K
The Proteasome Structure
699
The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...
The proteasome is an...
699
Protein-protein Interfaces
12.5K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
12.5K
